Celgene Corp. (NASDAQ:CELG)
2017 Stifel Healthcare Conference
November 14, 2017 02:45 PM ET
Executives
Scott Smith - President and COO
Terrie Curran - President, Inflammation and Immunology
Analysts
Tom Shrader - Stifel Nicolaus
Tom Shrader
Okay. Welcome back, everybody. So, this is the Stifel Healthcare Conference. I'm Tom Shrader, one of the biotech analysts. Next, we have Celgene. Quite a treat. It's quite a complicated story. So, the more time you can get with them, I think must feel the better. We have Scott Smith, the COO; Terrie Curran, Head of I&I; and Lisa Hayes from IR. And I'm glad to have all the audience questions you want. My plan is to more or less step through the therapeutic areas and try to see what we can learn. It will be a little bit pipeline-focused. I'm sure you're tired of questions about what you're going to use your balance sheet and for what so I won't ask any of those.
So, we'll start with multiple myeloma, a field you own but you may not own forever or you're certainly working hard to make that not the case. Maybe just your thoughts on how you see the field evolving because one of the things that you have a huge blockbuster that you won't have forever, but the plan is not really to replace it with another improved version. It is to get deeper into the biology. So just your thoughts about how that field will unfold.
